News and Press Releases
From Aqualung Therapeutics
-
First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb
Aqualung Therapeutics, announced that the first patient has been enrolled in a Phase 2A clinical trial evaluating the safety and efficacy of ALT-100 mAb for the treatment of adults with moderate/severe Acute Respiratory Distress Syndrome (ARDS) and Ventilator Induced Lung Injury. (VILI). The ALT-100 mAb is an investigational first-in-class monoclonal antibody therapeutic targeting extracellular NAMPT or eNAMPT, a master regulator of systemic inflammation and fibrosis that was identified by Dr. Garcia as a novel therapeutic target and major contributor to the severity of ARDS and other severe disorders characterized by inflammation and organ fibrosis.
-
Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
July 2023
-
From Pipeline to Commercialization - with Stan Miele
Stan shares his career journey from his previous roles to his current position in AQUALUNG THERAPEUTICS CORP as well as the ongoing development of AQUALUNG THERAPEUTICS CORP., an early-stage biotech company focused on addressing runaway or unchecked inflammation and fibrosis.
Listen to the full episode for deeper insights into the complexities and exciting potential of the health sector, as shared by Stan Mealy.
-
Aqualung Therapeutics awarded the AZBio 2022 Fast Lane Award
We are honored to be the recipient of the 2022 AZBio Fast Lane Award. As an early-stage biotech company, the support of the community is immensely impactful and appreciated.
-
Treating Respiratory Diseases & Inflammation w/ Stan Miele of Aqualung Therapeutics - BRT S04 EP14 (176) 4-2-2023
Business Round Table Interview with Aqualung CBO, Stan Miele
4/2/23
-
Aqualung Therapeutics Corp. Announces FDA Clearance of Investigational New Drug (IND) Application for ALT-100, a Novel mAb Therapy for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
September 2022
-
Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease
September 2022
-
Aqualung Therapeutics Receives the AZ-Bio Fast Lane Award and Achieves Key FDA-Related Milestones
September 2022
-
Aqualung Therapeutics Appoints Two New Board Directors
June 2022
-
Tucson startup looks to human trials for drug to treat lung inflammation
Jan 2022
-
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor
January 2022
-
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase
Dec 2021
-
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition
August 2021
-
Healing lungs, improving data, oncology research and more
June 2020